西妥昔单抗联合5-氟尿嘧啶治疗晚期大肠癌临床研究

Study on the efficacy of cetuximab combined 5-FU in treatment of advanced colorectal cancer

目的探讨西妥昔单抗联合5-氟尿嘧啶（5-FU）治疗晚期大肠癌临床研究，为晚期大肠癌的治疗提供更好的治疗方法。方法选取2011年12月至2013年6月收治的晚期大肠癌患者58例进行研究，按照临床试验随机对照的原则将患者随机分为两组，每组各29例，对照组采用含5-Fu进行治疗，观察组采用5-Fu联合西妥昔单抗进行治疗，观察两组患者客观生存率及安全性情况，以及随访1—3年后患者远期生存率情况。结果观察组和对照组患者完成放疗治疗的分别有28例和26例，其中观察组经治疗后完全缓解（CR）4例，部分缓解（PR）12例，病灶稳定（SD）10例，病情进展（PD）2例，其客观缓解率为57．14％，而对照组CR0例，PR9例，SD9例，PD8例，其客观缓解率为34．62％，两组相比，差异具有统计学意义（P〈0．05）；随访1年、3年，观察组生存率分别为96．43％和75．00％，而对照组患者生存率分别为84．62％和53．85％，两组相比，差异具有统计学意义（P〈0．05）；两组患者治疗期间不良反应相比，差异无统计学意义（P〉0．05）。结论西妥昔单抗联合5-Fu治疗晚期大肠癌疗效显著，显著提高了患者远期生存率，且安全性高，值得临床进一步研究。

Objective To explore the efficacy of cetuximab combined 5 - FU in treatment of advanced colorectal cancer, and to provide a better way for treatment of advanced colorectal cancer. Methods A total of 58 patients with advanced colorectal cancer during December 2008 to December 2010 in this hospital were allocated in this study. They were randomly divided into two groups, each group with 29 cases. Patients in control group were treated with 5 - FU, and patients in observation group were treated with 5 - FU combined cetuximab, the rates of survival and safety were objectively observed as well as long - term survival rate after follow - up for 1 ~ 3 years. Results Patients completed radiation therapy in observation group and control group were 28 cases and 26 cases respectively, including 4 cases with complete remission （CR）, 12 cases with partial remission （PR）, 10 cases with stable disease （SD） and 2 cases with progressive disease in observation group and the objective response rate was 57.14%, while in control group, CR was 0 case, PR in 9 cases, SD in 9 cases and PD in 8 cases, and its objective response rate was 34.62%, and the difference between these 2 groups was significant （ P 〈 0.05 ）. They had been followed up for 1 and 3 years, the survival rates in observation group were 96.43% and 75.00% respectively, while the survival rates of patients in control group were 84.62% and 53.85% respectively, and their difference was significant （ P 〈 O. 05 ）. Adverse reactions were compared during the treatment course of both groups, their difference was not statistically significant （ P 〉 0.05 ）. Conclusion The application of cetuximab combined 5 - FU in treatment of patients with advanced colorectal cancer had significant efficacy and safety, and it can significantly improve the long - term survival of patients, hence it is wor- thy to be further applied.